ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2018年09月03日 16時00分
Source:
Eisai
エーザイ、中心循環系血管内塞栓促進用補綴材「ディーシー ビーズ」使用目的又は効果の一部削除の承認について
東京, 2018年09月03日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、このたび、日本において、中心循環系血管内塞栓促進用補綴材「ディーシー ビーズ(R)」(高度管理医療機器、以下 本品)について、使用目的又は効果の一部削除が承認され、使用目的又は効果が「多血性腫瘍(子宮筋腫を除く)を有する患者に対する動脈塞栓療法」となりましたことをお知らせします。
今回の使用目的又は効果の一部削除の承認は、実臨床上、本品は「子宮筋腫」及び「動静脈奇形」に対して使用されないことから、関連学会に確認の上、当局と相談し、当該適応に係る使用目的又は効果の取り下げの一部変更承認申請を行っていたことに基づくものです。
当社は、本使用目的又は効果の一部削除に際し、医療関係者の皆様への適切な情報提供に努めてまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2018/news201876.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
MHI Receives Order for Additional 12 Units of the Outer Vertical Target for the Divertor Used in the ITER in Southern France
May 20, 2024 11:36 JST
Fujitsu chosen for GENIAC project, starts development of large language models for logical reasoning
May 17, 2024 14:03 JST
NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud
May 17, 2024 11:19 JST
Honda and IBM sign Memorandum of Understanding to Explore Long-term Joint Research and Development of Semiconductor Chip and Software Technologies for Future Software-Defined Vehicles
May 15, 2024 14:30 JST
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
May 15, 2024 11:19 JST
SMEIC Proposes to Acquire Shanghai Prime: A Catalyst for Developing a New Dual-Wheel Driver Pattern
May 14, 2024 21:54 JST
DENSO and Certhon Introduce Artemy, A Fully Automated Cherry Truss Tomato Harvesting Robot
May 14, 2024 11:02 JST
Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
May 13, 2024 18:32 JST
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
May 13, 2024 17:06 JST
Ogier and TOYOTA GAZOO Racing triumph again
May 13, 2024 14:36 JST
Spa points haul for TOYOTA GAZOO Racing
May 13, 2024 13:56 JST
DOCOMO to Launch NTT DOCOMO GLOBAL for Global Expansion
May 10, 2024 18:13 JST
Release of "Fugaku-LLM" - a large language model trained on the supercomputer "Fugaku"
May 10, 2024 12:20 JST
Paltalk, Inc. Reports Slight Increase in Revenue and 33% Reduction in Net Loss for First Quarter 2024
May 09, 2024 20:39 JST
Cordlife Accelerates Lab and Technical Staff Recruitment to Rebuild Foundation and Strengthen Core Processes in Singapore
May 09, 2024 19:00 JST
Honda Opens New R&D Facility in Bengaluru to Accelerate Electrification in India
May 09, 2024 14:13 JST
Fujitsu introduces "explainable AI" for use in genomic medicine and cancer treatment planning
May 09, 2024 10:41 JST
Mitsubishi Heavy Industries Increases Dividends on Back of Historically High FY2023 Results, Releases FY2024 Guidance
May 08, 2024 14:27 JST
Rome becomes the first European city to offer open loop transit payments to JCB Cardmembers
May 08, 2024 12:00 JST
NEC X Invests in Public Safety Startup Multitude Insights, Scaling AI-Powered Collaboration and Information Sharing for Law Enforcement
May 08, 2024 10:24 JST
More Latest Release >>
Related Release
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
5/15/2024 11:19:00 AM JST
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
5/13/2024 5:06:00 PM JST
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
4/18/2024 10:53:00 AM JST
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
4/17/2024 4:17:00 PM JST
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
4/3/2024 4:24:00 PM JST
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
4/1/2024 9:39:00 AM JST
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
3/29/2024 3:51:00 PM JST
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
3/29/2024 3:19:00 PM JST
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
3/29/2024 2:32:00 PM JST
Lifenet and Eisai Co-Develop Dementia Insurance "be"
3/21/2024 5:36:00 PM JST
More Press release >>